Transgene - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Transgene Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Transgene. The Group's principal activity is to discover and develop therapeutic vaccines. The Group develops gene-based vaccines used in treatment of cancer and infectious diseases. The Group follows three different strategies. The Group develops vaccines and partners with pharmaceutical companies for further development. The Group also independently develops and commercializes vaccines for certain special markets. The third strategy is to license vector technologies to companies with proprietary genes for short and medium term revenues. The Group markets the products under the brand names MYoDys, TG 4010, TG 4001, TG 1042 and TG 4040. The Group operates mainly in France.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report